Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids.

Domingo C, Moreno A, Mirapeix R.

Intern Med J. 2011 Jul;41(7):525-36. doi: 10.1111/j.1445-5994.2011.02481.x. Review.

PMID:
21762333
2.

Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.

Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R.

Curr Med Res Opin. 2011 Nov;27(11):2223-8. doi: 10.1185/03007995.2011.620950. Epub 2011 Sep 21.

PMID:
21933100
3.

Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.

Pelaia G, Gallelli L, Romeo P, Renda T, Busceti MT, Proietto A, Grembiale RD, Marsico SA, Maselli R, Vatrella A.

Int J Clin Pharmacol Ther. 2011 Dec;49(12):713-21.

PMID:
22122813
4.

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K.

Allergy. 2005 Mar;60(3):309-16.

5.

Effectiveness of omalizumab in non-allergic severe asthma.

Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM.

J Biol Regul Homeost Agents. 2013 Jan-Mar;27(1):45-53.

PMID:
23489686
6.

[Latin-American Consensus on Difficult-to-Control Asthma. 2008 Update].

[No authors listed]

Drugs Today (Barc). 2008 Jun;44 Suppl 3:1-43. Review. Spanish.

PMID:
19093041
7.

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).

Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM; QUALITX Study Investigators..

J Asthma. 2012 Apr;49(3):288-93. doi: 10.3109/02770903.2012.660297. Epub 2012 Feb 23.

PMID:
22356355
8.

Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.

Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C; Spanish Registry..

J Asthma. 2012 May;49(4):416-22. doi: 10.3109/02770903.2012.668255. Epub 2012 Mar 23.

PMID:
22443408
9.

Omalizumab in the treatment of asthma.

Tan R, Corren J.

Expert Rev Respir Med. 2011 Dec;5(6):747-56. doi: 10.1586/ers.11.73. Review.

PMID:
22082161
10.

Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation.

Sullivan PW, Campbell JD, Ghushchyan VH, Globe G, Lange J, Woolley JM.

J Asthma. 2015 Sep;52(7):669-80. doi: 10.3109/02770903.2015.1004683.

PMID:
25731600
11.
12.

Oral corticosteroid-dependent asthma: a 30-year review.

Randhawa I, Klaustermeyer WB.

Ann Allergy Asthma Immunol. 2007 Oct;99(4):291-302; quiz 302-3, 370. Review.

PMID:
17941275
13.

The relevance of IgE in the pathogenesis of allergy: the effect of an anti-IgE drug in asthma and other diseases.

Domingo C, Pacheco A, Hinojosa M, Bosque M.

Recent Pat Inflamm Allergy Drug Discov. 2007 Jun;1(2):151-64. Review.

PMID:
19075978
14.

Clinical experience with omalizumab in a Portuguese severe asthma unit.

Alfarroba S, Videira W, Galvão-Lucas C, Carvalho F, Bárbara C.

Rev Port Pneumol. 2014 Mar-Apr;20(2):78-83. doi: 10.1016/j.rppneu.2013.07.006. Epub 2014 Feb 10. English, Portuguese.

15.

Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma.

Sullivan PW, Campbell JD, Ghushchyan VH, Globe G.

Ann Allergy Asthma Immunol. 2015 Jun;114(6):462-9. doi: 10.1016/j.anai.2015.03.019. Epub 2015 Apr 15.

PMID:
25890451
17.

[The add-on effect of omalizumab on patients with uncontrolled bronchial asthma].

Minami Y, Endo S, Okumur S, Sasaki T, Yamamoto Y, Ogasa T, Osanai S, Ohsaki Y.

Nihon Kokyuki Gakkai Zasshi. 2011 Nov;49(11):793-9. Japanese.

PMID:
22171481
18.

Immunomodulatory and biologic therapies for severe refractory asthma.

Polosa R, Morjaria J.

Respir Med. 2008 Nov;102(11):1499-510. doi: 10.1016/j.rmed.2008.09.006. Review.

19.

Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.

[No authors listed]

Prescrire Int. 2007 Oct;16(91):179-82.

PMID:
17926440
20.

Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.

Rottem M.

J Asthma. 2012 Feb;49(1):78-82. doi: 10.3109/02770903.2011.637598. Epub 2011 Dec 7.

PMID:
22149205

Supplemental Content

Support Center